Aldeyra Therapeutics Inc
ALDX4.690USD
-0.120-2.49%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
282.16MMarket Cap
LossP/E TTM
More Details of Aldeyra Therapeutics Inc Company
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Aldeyra Therapeutics Inc Info
Ticker SymbolALDX
Company nameAldeyra Therapeutics Inc
IPO dateMay 02, 2014
CEODr. Todd C. Brady, M.D., Ph.D.
Number of employees9
Security typeOrdinary Share
Fiscal year-endMay 02
Address131 Hartwell Avenue
CityLEXINGTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02421
Phone17817614904
Websitehttps://www.aldeyra.com/
Ticker SymbolALDX
IPO dateMay 02, 2014
CEODr. Todd C. Brady, M.D., Ph.D.
Company Executives of Aldeyra Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.42M
+23.16%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Independent Director
14.81K
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Independent Director
Independent Director
--
--
Dr. Stephen G. Machatha, Ph.D.
Dr. Stephen G. Machatha, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Ben R. Bronstein, M.D.
Dr. Ben R. Bronstein, M.D.
Independent Director
Independent Director
--
--
Ms. Nancy B. Miller-Rich
Ms. Nancy B. Miller-Rich
Independent Director
Independent Director
--
--
Mr. William (Chip) Clark
Mr. William (Chip) Clark
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Alfieri
Mr. Michael (Mike) Alfieri
Principal Financial Officer and Principal Accounting Officer
Principal Financial Officer and Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.42M
+23.16%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Independent Director
14.81K
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Independent Director
Independent Director
--
--
Dr. Stephen G. Machatha, Ph.D.
Dr. Stephen G. Machatha, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
9.10%
Perceptive Advisors LLC
6.73%
The Vanguard Group, Inc.
5.97%
BlackRock Institutional Trust Company, N.A.
5.88%
Ardsley Advisory Partners LP
3.41%
Other
68.91%
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
9.10%
Perceptive Advisors LLC
6.73%
The Vanguard Group, Inc.
5.97%
BlackRock Institutional Trust Company, N.A.
5.88%
Ardsley Advisory Partners LP
3.41%
Other
68.91%
Shareholder Types
Shareholders
Proportion
Hedge Fund
19.07%
Investment Advisor
18.01%
Investment Advisor/Hedge Fund
11.66%
Private Equity
6.76%
Individual Investor
3.10%
Research Firm
2.16%
Family Office
0.25%
Pension Fund
0.18%
Bank and Trust
0.09%
Other
38.72%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
279
34.71M
57.96%
-3.49M
2025Q2
295
35.94M
60.00%
-7.70M
2025Q1
315
40.31M
67.37%
-4.94M
2024Q4
306
39.84M
66.72%
-5.42M
2024Q3
295
38.52M
64.82%
-5.60M
2024Q2
290
37.23M
62.65%
-8.21M
2024Q1
294
37.04M
62.88%
-7.70M
2023Q4
296
36.84M
62.63%
-6.52M
2023Q3
298
39.89M
68.07%
-12.41M
2023Q2
305
41.03M
70.05%
-8.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Knoll Capital Management, LLC
5.48M
9.14%
--
--
Jun 30, 2025
Perceptive Advisors LLC
4.05M
6.76%
-824.22K
-16.90%
Jun 30, 2025
The Vanguard Group, Inc.
3.50M
5.85%
-216.43K
-5.82%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.54M
5.91%
+127.13K
+3.73%
Jun 30, 2025
Ardsley Advisory Partners LP
2.05M
3.42%
+300.00K
+17.14%
Jun 30, 2025
AQR Capital Management, LLC
1.47M
2.46%
+1.08M
+275.44%
Jun 30, 2025
Brady (Todd C)
1.42M
2.38%
+267.69K
+23.16%
Apr 14, 2025
Kingdon Capital Management, L.L.C.
1.33M
2.22%
+552.79K
+70.96%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.15M
1.91%
+8.77K
+0.77%
Jun 30, 2025
683 Capital Management LLC
1.08M
1.8%
+604.00K
+126.89%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.43%
Vanguard US Momentum Factor ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares Micro-Cap ETF
0.05%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Global X Russell 2000 ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.43%
Vanguard US Momentum Factor ETF
Proportion0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
iShares Micro-Cap ETF
Proportion0.05%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
